salcoidosis salcoidosis
Conditions
Interventions
Sponsors
Konno Satoshi
Eligibility
Inclusion criteria
Inclusion criteria: Patients with sarcoidosis who are receiving outpatient care or hospitalized at Hokkaido University Hospital or JR Sapporo Hospital between the date of implementation approval and January 31, 2028
Exclusion criteria
Exclusion criteria: Patients meeting any of the following criteria shall be excluded from the study. Individuals with a history of progressive brain lesions Individuals concurrently receiving vagus nerve stimulation therapy Individuals with a history of severe cardiovascular disease Individuals with a history of glycerin hypersensitivity Pregnant or lactating individuals Individuals with a history of skin hypersensitivity or skin symptoms triggered by metals, etc. Individuals with difficulty ingesting orally Individuals using cardiac pacemakers or implantable cardioverter defibrillators (ICDs) Other individuals deemed unsuitable as research subjects by the principal investigator or co investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The presence or absence of lesion shrinkage at the treatment site, as evaluated by imaging studies, up to week 52 following low-frequency therapy administration | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in forced vital capacity and forced expiratory volume in one second measured by pulmonary function tests (pulmonary sarcoidosis) Changes in daily seizure frequency assessed by Holter electrocardiography Changes in biomarkers such as KL6, BNP, ACE, and lysozyme Presence or absence of worsening pulmonary lesions during low-frequency therapy Presence or absence of new lesions in different organs at each evaluation point Correlation between the state of inflammation and the expression status of clinically pathological factors and other analyzed molecules, as well as the presence or absence of disease-related gene variants and their association with the disease state. Correlation between the state of inflammation and the expression status of clinically pathological factors and other analyzed molecules. | — |
Contacts
Public ContactYuichi Kojima
Hokkaido University Hospital
Outcome results
None listed